RxDoctor Payments Data

Ashley Houk

Family · Galax, VANPI 1548676505

Payments from drug & device makers

$1,841in general payments, 2019–2025

Across 88 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$796
  • Pfizer$268
  • Novo Nordisk$165
  • Astellas Pharma US Inc$142
  • Mylan Specialty L.p.$91
  • Otsuka America Pharmaceutical, Inc.$66
  • plus $313 from 10 others

What the payments were for

  • Food & beverage$1,75095%
  • Education$915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,841 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$59,299
Medicare patients
193
Services billed
1,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol49$51,986
MounjaroTirzepatide34$41,834
OzempicSemaglutide36$33,432
EliquisApixaban19$27,098
TrulicityDulaglutide21$23,815
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$19,865
RexultiBrexpiprazole12$16,926
EntrestoSacubitril/Valsartan12$8,093
Tresiba Flextouch U-100Insulin Degludec11$5,497
Fluticasone Propionate HfaFluticasone Propionate13$4,558
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen78$2,590
Albuterol Sulfate HfaAlbuterol Sulfate94$2,536
Potassium Chloride22$1,628
Duloxetine Hcl71$1,260
Trazodone Hcl53$940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$796$71,85173 claims
Lilly USA, LLCMounjaro, Trulicity$52$65,64855 claims
Novo NordiskOzempic$165$33,43236 claims
PfizerEliquis$268$27,09819 claims
Otsuka America Pharmaceutical, Inc.Rexulti$66$16,92612 claims
NovartisEntresto$16$8,09312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.

Other family in Galax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →